Pfizer Inc. recently released positive results for its Reflections B7391003 study, which evaluated the safety and efficacy of PF-06439535 as compared to Avastin (bevacizumab).
PF-06439535, which Pfizer is developing as a potential biosimilar to Avastin, met its primary objective in the study. The drug demonstrated equivalence in objective response rate (ORR) when taken in combination with carboplatin/paclitaxel to fight advanced non-squamous non-small cell lung cancer.
ORR is defined as the proportion of patients who see a reduction in tumor size of a predefined amount over a minimum period of time.
“We are encouraged by this data, and its importance in helping to advance physician confidence in, and understanding of, the potential value of biosimilar medicines for cancer patients around the world,” Dr. Salomon Azoulay, senior vice president and chief medical officer at Pfizer Essential Health, said in a statement. “As Pfizer’s second proposed oncology monoclonal antibody biosimilar to achieve positive top line data results, we continue to focus on and commit to advancing our pipeline of proposed biosimilars, with the goal of expanding patient access to these important therapeutic options.”